The Evidence
Multiple randomized controlled trials have shown cannabis (smoked, vaporized, and oral) reduces neuropathic pain in adults. The pooled effect size is moderate but clinically meaningful, and consistent across HIV-associated neuropathy, diabetic peripheral neuropathy, post-herpetic neuralgia, and chemotherapy-induced peripheral neuropathy.
- Abrams 2007 — smoked cannabis reduced HIV-associated neuropathy pain by ~30% vs. placebo.
- Wilsey 2008, 2013 — vaporized cannabis at low and medium doses reduced neuropathic pain in placebo-controlled trials.
- Wallace 2015 — vaporized cannabis showed dose-response benefit in painful diabetic peripheral neuropathy.
- Sativex (nabiximols) trials — multiple RCTs in MS-associated neuropathic pain support its use; approved in 29+ countries.
The NASEM committee concluded: "There is conclusive or substantial evidence that cannabis or cannabinoids are effective for the treatment of chronic pain in adults" — with neuropathic pain being the most consistently demonstrated component.
Common Neuropathies Affecting Older Adults
Diabetic Peripheral Neuropathy
Affects ~50% of people with longstanding diabetes. Symptoms: burning, tingling, electric-shock-like pain, often in feet and hands ("stocking-glove" distribution). Standard first-line therapies (gabapentin, pregabalin, duloxetine, topical lidocaine) work for some but leave many patients undertreated.
Cannabis (especially balanced THC:CBD products) is a reasonable add-on or alternative when standard agents fail or produce intolerable side effects.
Post-Herpetic Neuralgia (PHN)
Persistent burning or shooting pain after shingles, often along a dermatomal distribution. Older adults are at highest risk because shingles itself becomes more common with age. PHN can persist for months to years.
Topical lidocaine, capsaicin, gabapentinoids, and tricyclics are first-line. Cannabis is an evidence-based add-on for refractory cases.
Chemotherapy-Induced Peripheral Neuropathy (CIPN)
Numbness, tingling, and pain in the hands and feet caused by certain chemotherapy regimens (taxanes, platinum agents, vincristine). Often persists after chemotherapy ends. Standard treatment options are limited; duloxetine is the only ASCO-endorsed first-line agent.
Cannabis evidence in CIPN specifically is thinner than in DPN or PHN, but the mechanism is similar and clinical use is common in oncology palliative care. See Cannabis in Cancer Care.
Other Neuropathies
- Trigeminal neuralgia — intense facial pain; cannabis evidence is thin but mechanism is plausible.
- Idiopathic small-fiber neuropathy — increasingly recognized in older adults; standard agents often inadequate.
- Postsurgical neuropathic pain — nerve damage from joint replacement, hernia repair, mastectomy. Evidence is limited but the underlying mechanism overlaps with conditions where cannabis works.
How to Use It
Sublingual / Oral
Best starting point for older adults. Predictable onset (15–45 min sublingual, 30–120 min edible), predictable duration (4–8 hours sublingual, 6–12 hours edible), no respiratory cost.
- Balanced 1:1 THC:CBD tincture: 2–5 mg of each cannabinoid sublingually, twice daily. Titrate up weekly.
- CBD-dominant tincture if THC is undesirable or contraindicated: 15–50 mg twice daily.
- Low-dose THC edible for evening pain control: 2.5–5 mg at first, increasing as tolerated.
Topical
For localized neuropathic pain (a single dermatome, focal foot pain, post-surgical site), cannabis topicals can supplement systemic treatment. Limited systemic absorption, no psychoactivity. See Cannabis Topicals.
Vaporized / Inhaled
Best for acute breakthrough pain due to rapid onset (seconds to minutes). Vaporization at 180–210°C avoids combustion byproducts. Less ideal as a maintenance therapy because frequent dosing is required.
Drug Interactions
Most patients with diabetic or post-herpetic neuropathy are on one or more of: gabapentin/pregabalin, duloxetine, amitriptyline/nortriptyline, tramadol, opioids, lidocaine patches, capsaicin cream, anticonvulsants.
- Gabapentinoids + cannabis — additive sedation; reduce starting cannabis dose.
- Tricyclics + cannabis — additive anticholinergic effects (dry mouth, constipation, confusion).
- Duloxetine + CBD — CBD inhibits CYP enzymes that metabolize duloxetine; theoretical risk of higher levels.
- Opioids + cannabis — additive sedation. Evidence suggests cannabis may allow opioid dose reduction in some patients ("opioid-sparing"), but risk monitoring matters.
- Tramadol + cannabis — both lower seizure threshold; both sedating.
See full Cannabis Drug Interactions overview.
Realistic Expectations
Cannabis for neuropathy is best framed as a moderately effective add-on, not a cure. In trials, ~30% pain reduction is the typical pooled result — comparable to gabapentinoids and slightly better than placebo’s ~15% reduction, but well short of complete relief. For many patients, the most useful framing is: "Will adding this allow me to lower my opioid or gabapentinoid dose, sleep better, or get more functional hours per day?" If yes, the addition is worthwhile.
Bottom Line
Cannabis for neuropathic pain has the strongest evidence in cannabis medicine — conclusive or substantial per NASEM. Diabetic peripheral neuropathy, post-herpetic neuralgia, and MS-associated neuropathic pain are the best-studied. Older adults specifically should start with sublingual balanced THC:CBD or CBD-dominant products, coordinate carefully with their pharmacist about gabapentinoid/SNRI/opioid interactions, and frame success in functional terms rather than expecting full pain elimination.